Medication info

Rinaploem Controlled Release Tablets 12.5/2.5/1000 mg (Empagliflozin, Linagliptin, Metformin Hydrochloride)

Prescription medicationTablet
Ingredient · strength
Empagliflozin›12.5mg / 1 tabletLinagliptin Micronized›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Dongkwang Pharmaceutical Co., Ltd.
Appearance
White and light blue, oval, film-coated tablets with a double convex surface.
Packaging
Bottle packaging - 30 tablets/bottle
Approval status
Active

MFDS item code 202502781 · Approved 2025.10.28

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum daily dose of each component: empagliflozin 25mg, linagliptin 5mg, and extended-release metformin hydrochloride 2000mg. This drug should be taken once daily in the evening with a meal to reduce gastrointestinal adverse reactions caused by metformin hydrochloride. If adjustment of the metformin hydrochloride dose is necessary, the dose should be adjusted gradually. Patients taking this drug as 10/5/1000mg or 25/5/1000mg extended-release tablets should take 1 tablet once daily. Patients taking this drug as 5/2.5/1000mg or 12.5/2.5/1000mg extended-release tablets should take 2 tablets once daily. For patients who tolerate the recommended starting dose of this drug, empagliflozin 10mg/linagliptin 5mg/metformin hydrochloride 1000mg once daily, but need additional glycemic control, the dose of empagliflozin or metformin may be increased. Patients switching from concomitant therapy with empagliflozin, linagliptin, and metformin hydrochloride to this drug should receive the same doses they were taking previously. The safety and efficacy of this drug have not been specifically evaluated in patients switching from other antihyperglycemic agents. Because this may cause changes in glycemic control, any change in treatment for patients with type 2 diabetes should be made under careful monitoring. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. To maintain its extended-release properties, this drug must be swallowed whole and must not be split, crushed, ground, or chewed. This drug may not dissolve completely and may be excreted in the stool. It is not known whether the substance excreted in the stool contains the active ingredients of the drug. If a patient repeatedly reports finding this drug in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Special Populations Patients with Renal Impairment The efficacy and safety of this drug vary according to renal function, and dose adjustment based on renal function is necessary. Therefore, assessment of renal function before starting this drug and periodically during treatment is recommended. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this drug may be used by adjusting the dose of metformin hydrochloride, one of its components, provided it is well tolerated and the patient does not have other conditions that may increase the risk of lactic acidosis. The starting dose of extended-release metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If the estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, this drug should be discontinued immediately. Renal function should be assessed every 3~6 months.

Ingredients

Manufacturer
Dongkwang Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used in conjunction with diet and exercise to improve blood sugar control in patients with type 2 diabetes. It contains a combination of three ingredients: empagliflozin, linagliptin, and metformin, which work together to assist in blood sugar management and effectively maintain stable blood sugar levels. Therefore, this medication is used to enhance blood sugar control in patients with type 2 diabetes.

Dosage and Administration

Adult dosage

For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum daily dose of each component: empagliflozin 25mg, linagliptin 5mg, and extended-release metformin hydrochloride 2000mg. This drug should be taken once daily in the evening with a meal to reduce gastrointestinal adverse reactions caused by metformin hydrochloride. If adjustment of the metformin hydrochloride dose is necessary, the dose should be adjusted gradually. Patients taking this drug as 10/5/1000mg or 25/5/1000mg extended-release tablets should take 1 tablet once daily. Patients taking this drug as 5/2.5/1000mg or 12.5/2.5/1000mg extended-release tablets should take 2 tablets once daily. For patients who tolerate the recommended starting dose of this drug, empagliflozin 10mg/linagliptin 5mg/metformin hydrochloride 1000mg once daily, but need additional glycemic control, the dose of empagliflozin or metformin may be increased. Patients switching from concomitant therapy with empagliflozin, linagliptin, and metformin hydrochloride to this drug should receive the same doses they were taking previously. The safety and efficacy of this drug have not been specifically evaluated in patients switching from other antihyperglycemic agents. Because this may cause changes in glycemic control, any change in treatment for patients with type 2 diabetes should be made under careful monitoring. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. To maintain its extended-release properties, this drug must be swallowed whole and must not be split, crushed, ground, or chewed. This drug may not dissolve completely and may be excreted in the stool. It is not known whether the substance excreted in the stool contains the active ingredients of the drug. If a patient repeatedly reports finding this drug in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Special Populations Patients with Renal Impairment The efficacy and safety of this drug vary according to renal function, and dose adjustment based on renal function is necessary. Therefore, assessment of renal function before starting this drug and periodically during treatment is recommended. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this drug may be used by adjusting the dose of metformin hydrochloride, one of its components, provided it is well tolerated and the patient does not have other conditions that may increase the risk of lactic acidosis. The starting dose of extended-release metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If the estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, this drug should be discontinued immediately. Renal function should be assessed every 3~6 months.

Precautions

This medication can cause a rare side effect known as severe lactic acidosis, which may threaten life; therefore, caution is required. The risk of lactic acidosis is particularly high in patients with significantly impaired kidney function or those with heart, liver, or lung dysfunction. Therefore, this medication should not be used in patients with severely impaired kidney function, those undergoing dialysis, patients with acute metabolic acidosis, or patients with severe heart failure. Additionally, patients who are about to undergo surgery, or those with severe infections, dehydration, or excessive alcohol intake should temporarily pause the use of this medication. There may be an increased risk of hypoglycemia if this drug is used in combination with other medications that lower blood sugar; if taking insulin or sulfonylureas alongside this medication, dose adjustments may be necessary. During treatment with this medication, regular blood tests should be conducted to monitor kidney function and vitamin B12 levels, and any abnormal symptoms should be promptly reported to the medical staff. Furthermore, this medication may increase the risk of urinary tract infections or genital fungal infections; if related symptoms occur, prompt treatment should be sought. Elderly patients or those at risk of reduced fluid volume should be cautious about dehydration and hypotension, and should consult a physician if any symptoms arise. This medication should be swallowed whole and not chewed or crushed; in some patients, the tablet coating may be excreted in stool, which is not a cause for concern. Caution is necessary when driving or operating machinery due to the risk of hypoglycemia, especially when combined with other blood sugar-lowering agents. It is advisable to avoid alcohol consumption during treatment, as acute or chronic excessive alcohol intake may increase the risk of lactic acidosis. Lastly, there may be interactions with other medications used in conjunction with this one, so it is essential to inform healthcare providers of all medications being taken.

Side effects

  • Lactic acidosis
  • urinary tract infection
  • pyelonephritis
  • urosepsis
  • vaginitis
  • vulvitis
  • balanitis
  • genital infection
  • perineal necrosis
  • hypersensitivity reaction
Show 163 more
  • angioedema
  • urticaria
  • hypoglycemia
  • thirst
  • ketoacidosis
  • cough
  • constipation
  • pancreatitis
  • oral ulcerations
  • pruritus
  • rash
  • vesicular pemphigoid
  • rhabdomyolysis
  • reduced fluid volume
  • increased urination
  • dysuria
  • interstitial nephritis
  • increased amylase
  • increased lipase
  • increased hematocrit
  • increased serum lipids
  • vitamin B12 deficiency
  • taste disturbance
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • anorexia
  • erythema
  • urticaria
  • rash
  • constipation
  • epigastric pain
  • enterocolitis
  • bowel obstruction
  • gastritis
  • shingles
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorder
  • Alzheimer's type dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • abdominal pain
  • gastrointestinal disorders
  • irritable bowel syndrome
  • burning mouth syndrome
  • colitis
  • abdominal discomfort
  • dysphagia
  • gastric ulcer
  • gum bleeding
  • tooth loss
  • hemorrhoids
  • lower abdominal pain
  • diarrhea
  • vomiting
  • gastritis
  • gastrointestinal disorders
  • acute pyelonephritis
  • leukoplakia
  • rhinitis
  • soft tissue infection
  • pharyngitis
  • tsutsugamushi disease
  • periodontitis
  • tonsillitis
  • laryngitis
  • viral upper respiratory infection
  • pneumonia
  • tonsillitis
  • headache
  • dizziness
  • drowsiness
  • anxiety
  • depression
  • insomnia
  • increased blood pressure
  • hearing loss
  • erectile dysfunction
  • goiter
  • anemia
  • lymphadenopathy
  • vulvar pruritus
  • genital pruritus
  • dyslipidemia
  • hyponatremia
  • dermal cysts
  • seborrheic dermatitis
  • atopic dermatitis
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • macular fibrosis
  • eye discomfort
  • conjunctival hyperemia
  • pathological myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • full-thickness retinal detachment
  • eyelid edema
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exertional dyspnea
  • moist cough
  • allergic rhinitis
  • residual phlegm
  • skin laceration
  • rib fracture
  • ligamentous strain syndrome
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • arteriosclerosis
  • deep vein thrombosis
  • diabetic vascular disorders
  • peripheral arterial occlusive disease
  • unstable angina
  • hypertension
  • insomnia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a sealed container. To maintain the efficacy of the medication, it is recommended to store it at room temperature, between 1 degree Celsius and 30 degrees Celsius.

Appearance and packaging

Appearance

White and light blue, oval, film-coated tablets with a double convex surface.

Package unit

Bottle packaging - 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.